CTOR
Citius Oncology·NASDAQ
--
--(--)
--
--(--)
0.81 / 10
Underperform
Fundamental assessment is poor (0.8/10). Key issues include negative asset-to-market-value and revenue-to-market-value ratios, low current-assets turnover, and deeply negative net-profit margins. While year-over-year revenue growth is high at 45.97%, it is outweighed by profitability and efficiency concerns, leading to a selective 'underperform' rating.
Analysis Checks(2/10)
Revenue-MV
Value-0.26
Score0/3
Weight9.24%
1M Return-2.92%
Value-0.26
Score0/3
Weight9.24%
1M Return-2.92%
Total operating revenue (YoY growth rate %)
Value45.97
Score0/3
Weight13.86%
1M Return-6.59%
Value45.97
Score0/3
Weight13.86%
1M Return-6.59%
Net income-Revenue
Value-0.17
Score1/3
Weight1.91%
1M Return-0.69%
Value-0.17
Score1/3
Weight1.91%
1M Return-0.69%
Current assets turnover ratio
Value2.56
Score1/3
Weight4.65%
1M Return-1.72%
Value2.56
Score1/3
Weight4.65%
1M Return-1.72%
Asset-MV
Value-0.50
Score2/3
Weight1.29%
1M Return-0.42%
Value-0.50
Score2/3
Weight1.29%
1M Return-0.42%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight4.27%
1M Return-1.63%
Value100.00
Score2/3
Weight4.27%
1M Return-1.63%
Net cash flow from operating activities / Operating revenue (%)
Value-1393.65
Score0/3
Weight16.00%
1M Return-7.70%
Value-1393.65
Score0/3
Weight16.00%
1M Return-7.70%
Net profit margin (%)
Value-1256.29
Score0/3
Weight16.67%
1M Return-8.03%
Value-1256.29
Score0/3
Weight16.67%
1M Return-8.03%
EBIT / Total operating revenue (%)
Value-512.37
Score0/3
Weight15.77%
1M Return-7.44%
Value-512.37
Score0/3
Weight15.77%
1M Return-7.44%
Net profit / Total operating revenue (%)
Value-265.09
Score0/3
Weight16.35%
1M Return-7.85%
Value-265.09
Score0/3
Weight16.35%
1M Return-7.85%
Revenue-MV
Value-0.26
Score0/3
Weight9.24%
1M Return-2.92%
Value-0.26
Score0/3
Weight9.24%
1M Return-2.92%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight4.27%
1M Return-1.63%
Value100.00
Score2/3
Weight4.27%
1M Return-1.63%
Total operating revenue (YoY growth rate %)
Value45.97
Score0/3
Weight13.86%
1M Return-6.59%
Value45.97
Score0/3
Weight13.86%
1M Return-6.59%
Net cash flow from operating activities / Operating revenue (%)
Value-1393.65
Score0/3
Weight16.00%
1M Return-7.70%
Value-1393.65
Score0/3
Weight16.00%
1M Return-7.70%
Net income-Revenue
Value-0.17
Score1/3
Weight1.91%
1M Return-0.69%
Value-0.17
Score1/3
Weight1.91%
1M Return-0.69%
Net profit margin (%)
Value-1256.29
Score0/3
Weight16.67%
1M Return-8.03%
Value-1256.29
Score0/3
Weight16.67%
1M Return-8.03%
Current assets turnover ratio
Value2.56
Score1/3
Weight4.65%
1M Return-1.72%
Value2.56
Score1/3
Weight4.65%
1M Return-1.72%
EBIT / Total operating revenue (%)
Value-512.37
Score0/3
Weight15.77%
1M Return-7.44%
Value-512.37
Score0/3
Weight15.77%
1M Return-7.44%
Asset-MV
Value-0.50
Score2/3
Weight1.29%
1M Return-0.42%
Value-0.50
Score2/3
Weight1.29%
1M Return-0.42%
Net profit / Total operating revenue (%)
Value-265.09
Score0/3
Weight16.35%
1M Return-7.85%
Value-265.09
Score0/3
Weight16.35%
1M Return-7.85%
Is CTOR undervalued or overvalued?
- CTOR scores 0.81/10 on fundamentals and holds a Premium valuation at present. Backed by its -54.42% ROE, 0.00% net margin, -4.03 P/E ratio, 2.22 P/B ratio, and -9.68% earnings growth, these metrics solidify its Underperform investment rating.
